GIANT BIOGENE(02367.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 939.71 million, YoY decrease of 20.5%

NewTimeSpace News: August 18, 2026, GIANT BIOGENE(02367.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 2.92 billion, decreased by 6.26% YoY; Net Profit stood at CNY 939.53 million, YoY decrease of 20.54%; Profit Attributable to Shareholders stood at CNY 939.71 million, YoY decrease of 20.5%; Basic Earnings Per Share (EPS) stood at CNY 0.89.

In terms of profitability, GIANT BIOGENE Gross Profit changed from CNY 2.54 billion in the same period last year to CNY 2.32 billion in the current period, decreased by CNY 223.94 million; gross profit margin changed from 81.68% in the same period last year to 79.46% in the current period, decreased by 2.22 percentage points; net profit changed from CNY 1.18 billion in the same period last year to CNY 939.53 million in the current period, decreased by CNY 242.92 million; net profit margin changed from 37.99% in the same period last year to 32.2% in the current period, decreased by 5.79 percentage points.

In terms of earnings quality, GIANT BIOGENE Operating Profit changed from CNY 1.44 billion in the same period last year to CNY 1.09 billion in the current period, decreased by CNY 358.97 million; Operating Profit Margin changed from 46.4% in the same period last year to 37.2% in the current period, decreased by 9.2 percentage points.

In terms of financial soundness, GIANT BIOGENE Debt-to-Asset Ratio changed from 18.58% in the same period last year to 8.52% in the current period, decreased by 10.07 percentage points; Total Equity changed from CNY 9.189 billion in the same period last year to CNY 9.371 billion in the current period, increased by CNY 182.32 million; Current Liabilities changed from CNY 2.03 billion in the same period last year to CNY 781.78 million in the current period, decreased by CNY 1.25 billion; Quick Ratio changed from 4.65 in the same period last year to 10.18 in the current period, increased by 5.53 percentage points.

In terms of R&D investment focus, GIANT BIOGENE R&D Expenses changed from CNY 41.18 million in the same period last year to CNY 45.52 million in the current period, increased by CNY 4.34 million; R&D to Total Revenue Ratio changed from 1.32% in the same period last year to 1.56% in the current period, increased by 0.24 percentage points.

By the close of trading on August 18, 2026, GIANT BIOGENE(02367) saw a loss of 5.64% in its share price, closing at HKD 28.1. The full-day turnover stood at HKD 176.62 million, showing significant volume increase, with the latest market capitalization at HKD 29.83 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.